Skip to Main Content

Eosinophils have received considerable attention from the research community in the last decade, in large part, as a result of their potential role in asthma. The concept of the eosinophil as a cell that has protective effects against helminthic parasite infection but can cause tissue damage when inappropriately activated remains intact, although the evidence for both these roles is circumstantial. Eosinophil production and function are profoundly influenced by interleukin-5 (IL-5), and thus eosinophilia is associated with diseases characterized by T-helper (Th) 2-mediated immune responses, fostering B-lymphocyte function, including infections by helminthic parasites and extrinsic asthma. However, eosinophilia also occurs in diseases not obviously associated with Th2 dominance such as intrinsic asthma, the hypereosinophilic syndrome (HES), and inflammatory bowel disease. Thus, IL-5 and other eosinophil mediators can be generated in various types of inflammatory response.

The eosinophil, like other leukocytes, can generate proinflammatory mediators. Eosinophil-specific granule proteins are toxic for a range of mammalian cells and parasitic larvae. Eosinophils, like mast cells, produce sulfidopeptide leukotrienes, as well as other lipid mediators, such as platelet-activating factor (PAF). Cytokine production by eosinophils broadens their potential functions, for example in wound healing through the generation of transforming growth factor (TGF)-α. Synthesis of TGF-β may explain the propensity of eosinophils to be associated with fibrotic reactions such as endomyocardial fibrosis, characteristic of HES, and fibrosing alveolitis.

Considerable effort has gone into trying to unravel the molecular basis of eosinophil tissue recruitment. The selective accumulation of eosinophils is the result of a concerted and integrated series of events involving their production in the marrow and egress therefrom, adhesion to endothelium, selective chemotaxis, and prolonged survival in tissues. These events are controlled, either directly or indirectly, by production of IL-4, IL-5, and IL-13.

The discovery that a proportion of patients with HES have either a clonal abnormality resulting from the creation of a constitutively active novel tyrosine kinase (FIP1L1-PDGFRα) or a T-cell lymphoproliferative disease causing a reactive eosinophilia has offered the prospect of new and more effective treatments for this condition as well as giving dramatic new insights into the control

of eosinophil production. There has long been a debate about the extent to which eosinophils cause tissue damage, are innocent bystanders, or even help to ameliorate the condition. This is now being resolved with data showing that specific reduction in eosinophils using anti-IL-5 monoclonal antibody is beneficial in eosinophilic airway disease and hypereosinophilic syndromes.

Acronyms and Abbreviations

Acronyms and abbreviations that appear in this chapter include: ABPA, allergic bronchopulmonary aspergillosis; CCR, chemokine receptor; CEL, chronic eosinophilic leukemia; CMPD, chronic myeloproliferative disease; ECF-A, eosinophil chemotactic factor of anaphylaxis; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; EPO, eosinophil peroxidase; GM-CSF, granulocyte-monocyte colony-stimulating growth factor; HES, hypereosinophilic syndrome; HLA, human leukocyte antigen; ICAM, intercellular adhesion molecule; IL, interleukin; LAMP, lysosome-associated membrane protein; LIMP, lysosome integral membrane protein; mAb, monoclonal antibody; MBP, ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.